KD Logo

News: Adaptimmune Therapeutics Plc ADR’s Chief Commercial Officer Piccina Cintia reduceds 24,531 shares

In a filing, Adaptimmune Therapeutics Plc ADR revealed its Chief Commercial Officer Piccina Cintia unloaded Company’s shares for reported $22814.0 on Jun 18 ’24. In the deal valued at $0.93 per share,24,531 shares were sold. As a result of this transaction, Piccina Cintia now holds 38,293 shares worth roughly $40207.65.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Rawcliffe Adrian sold 30,080 shares, generating $20,244 in total proceeds. Upon selling the shares at $0.67, the Chief Executive Officer now owns 44,848 shares.

Before that, Bertrand William C JR sold 18,908 shares. Adaptimmune Therapeutics Plc ADR shares valued at $12,725 were divested by the Chief Operating Officer at a price of $0.67 per share. As a result of the transaction, Bertrand William C JR now holds 7,785 shares, worth roughly $8174.25.

Scotiabank initiated its Adaptimmune Therapeutics Plc ADR [ADAP] rating to a Sector outperform in a research note published on May 30, 2024; the price target was $3.15. A number of analysts have revised their coverage, including Bryan Garnier’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. Guggenheim also remained covering ADAP and has increased its forecast on January 03, 2023 with a “Buy” recommendation from previously “Neutral” rating. Mizuho revised its rating on November 09, 2022. It rated ADAP as “a Buy” which previously was an “a Neutral”.

Price Performance Review of ADAP

On Tuesday, Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] saw its stock unchanged to $1.05. Over the last five days, the stock has gained 21.26%. Adaptimmune Therapeutics Plc ADR shares have risen nearly 32.41% since the year began. Nevertheless, the stocks have risen 13.51% over the past one year. While a 52-week high of $2.05 was reached on 03/08/24, a 52-week low of $0.42 was recorded on 01/17/24. SMA at 50 days reached $1.0574, while 200 days put it at $0.9442. A total of 1.61 million shares were traded, compared to the trading of 1.6 million shares in the previous session.

Levels Of Support And Resistance For ADAP Stock

The 24-hour chart illustrates a support level at 1.0200, which if violated will result in even more drops to 0.9900. On the upside, there is a resistance level at 1.0900. A further resistance level may holdings at 1.1300. The Relative Strength Index (RSI) on the 14-day chart is 55.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0747, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 18.18%. Stochastics%K at 76.28% indicates the stock is a holding.

The most recent change occurred on May 28, 2021 when Barclays began covering the stock and recommended ‘”an Underweight”‘ rating along with a $4 price target.

Most Popular